Physician profile
Mazen Nashed
NPI 1124114574
$14,277.00
in general payments reported to CMS, 2019-2025
52 companies · $87.55 in 2025
The $87.55 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,130 · 2020: $2,504 · 2021: $2,494 · 2022: $2,491 · 2023: $2,572 · 2024: $1,999 · 2025: $87.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,658.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,449.48 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $1,301.71 | 2019-2024 | Ultomiris, Soliris |
| Teva Pharmaceuticals USA, INC. | $1,224.23 | 2020-2024 | Austedo Xr, Austedo, Ajovy |
| Novo Nordisk INC | $1,111.09 | 2019-2024 | Ozempic, Rybelsus |
| Jazz Pharmaceuticals INC. | $877.44 | 2019-2024 | |
| Mdd US Operations, LLC | $574.05 | 2021-2024 | Gocovri |
| Novartis Pharmaceuticals Corporation | $565.19 | 2019-2023 | |
| Amgen INC. | $524.96 | 2019-2022 | |
| Lundbeck LLC | $510.34 | 2019-2024 | Vyepti |
| Biogen, INC. | $491.84 | 2021-2024 | Tysabri, Vumerity |
| Lilly USA, LLC | $485.36 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Sunovion Pharmaceuticals INC. | $462.33 | 2019-2021 | |
| Argenx US, INC. | $369.73 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Greenwich Biosciences, INC. | $323.16 | 2019-2020 | |
| Kyowa Kirin, INC. | $303.41 | 2020-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Nashed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.